{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T16:27:55Z","timestamp":1794414475994,"version":"4.9.1"},"reference-count":110,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002241","name":"Japan Science and Technology Agency","doi-asserted-by":"publisher","award":["JPMJFR2350"],"award-info":[{"award-number":["JPMJFR2350"]}],"id":[{"id":"10.13039\/501100002241","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002241","name":"Japan Science and Technology Agency","doi-asserted-by":"publisher","award":["JPMJFR230F"],"award-info":[{"award-number":["JPMJFR230F"]}],"id":[{"id":"10.13039\/501100002241","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","award":["26K02216"],"award-info":[{"award-number":["26K02216"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","award":["25H01855"],"award-info":[{"award-number":["25H01855"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","award":["24K10076"],"award-info":[{"award-number":["24K10076"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","award":["24KK0150"],"award-info":[{"award-number":["24KK0150"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","award":["25KJ0155"],"award-info":[{"award-number":["25KJ0155"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP25gm0010011s0102"],"award-info":[{"award-number":["JP25gm0010011s0102"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP24fk0210154s0501"],"award-info":[{"award-number":["JP24fk0210154s0501"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP25fk0210178h0001"],"award-info":[{"award-number":["JP25fk0210178h0001"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.pharmthera.2026.109123","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T23:10:29Z","timestamp":1788995429000},"page":"109123","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Cell death-induced chronic inflammation as a therapeutic target for metabolic dysfunction-associated steatohepatitis"],"prefix":"10.1016","volume":"288","author":[{"given":"Takayoshi","family":"Suganami","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miyako","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiko","family":"Itoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2026.109123_bb0005","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aba1983","article-title":"Single-cell RNA-seq reveals ectopic and aberrant lung-resident cell populations in idiopathic pulmonary fibrosis","volume":"6","author":"Adams","year":"2020","journal-title":"Science Advances"},{"key":"10.1016\/j.pharmthera.2026.109123_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.arcmed.2024.103043","article-title":"Global prevalence of nonalcoholic fatty liver disease: An updated review meta-analysis comprising a population of 78 million from 38 countries","volume":"55","author":"Amini-Salehi","year":"2024","journal-title":"Archives of Medical Research"},{"key":"10.1016\/j.pharmthera.2026.109123_bb0015","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1038\/s41467-020-16092-0","article-title":"Hepatocyte mitochondria-derived danger signals directly activate hepatic stellate cells and drive progression of liver fibrosis","volume":"11","author":"An","year":"2020","journal-title":"Nature Communications"},{"key":"10.1016\/j.pharmthera.2026.109123_bb0020","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1053\/j.gastro.2015.04.043","article-title":"Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease","volume":"149","author":"Angulo","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.pharmthera.2026.109123_bb0025","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.cgh.2023.04.003","article-title":"Cenicriviroc lacked efficacy to treat liver fibrosis in nonalcoholic steatohepatitis: AURORA phase III randomized study","volume":"22","author":"Anstee","year":"2024","journal-title":"Clinical Gastroenterology and Hepatology"},{"key":"10.1016\/j.pharmthera.2026.109123_bb0030","article-title":"Sterol O-acyltransferase (SOAT\/ACAT) activity is required to form cholesterol crystals in hepatocyte lipid droplets","volume":"1869","author":"Bairos","year":"2024","journal-title":"Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids"},{"key":"10.1016\/j.pharmthera.2026.109123_bb0035","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1016\/j.cgh.2019.12.026","article-title":"Nonalcoholic fatty liver disease and fibrosis associated with increased risk of cardiovascular events in a prospective study","volume":"18","author":"Baratta","year":"2020","journal-title":"Clinical Gastroenterology and Hepatology"},{"key":"10.1016\/j.pharmthera.2026.109123_bb0040","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/hep.20051","article-title":"Apoptosis: The nexus of liver injury and fibrosis","volume":"39","author":"Canbay","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmthera.2026.109123_bb0045","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1194\/jlr.M500294-JLR200","article-title":"Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans","volume":"46","author":"Cinti","year":"2005","journal-title":"Journal of Lipid Research"},{"key":"10.1016\/j.pharmthera.2026.109123_bb0050","doi-asserted-by":"crossref","first-page":"355","DOI":"10.3389\/fncel.2017.00355","article-title":"Cyclodextrins and iatrogenic hearing loss: New drugs with significant risk","volume":"11","author":"Crumling","year":"2017","journal-title":"Frontiers in Cellular Neuroscience"},{"key":"10.1016\/j.pharmthera.2026.109123_bb0055","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1016\/j.jhep.2020.06.025","article-title":"Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials","volume":"73","author":"Davison","year":"2020","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.pharmthera.2026.109123_bb0060","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1038\/s41467-023-36375-6","article-title":"Cholesterol esters form supercooled lipid droplets whose nucleation is facilitated by triacylglycerols","volume":"14","author":"Dumesnil","year":"2023","journal-title":"Nature Communications"},{"key":"10.1016\/j.pharmthera.2026.109123_bb0065","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1002\/hep.27368","article-title":"Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up","volume":"61","author":"Ekstedt","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmthera.2026.109123_bb0070","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement","volume":"73","author":"Eslam","year":"2020","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.pharmthera.2026.109123_bb0075","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"EASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","author":"European Association for the Study of the, L","year":"2024","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.pharmthera.2026.109123_bb0080","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.add8945","article-title":"Identification of a broadly fibrogenic macrophage subset induced by type 3 inflammation","volume":"8","author":"Fabre","year":"2023","journal-title":"Science Immunology"},{"key":"10.1016\/j.pharmthera.2026.109123_bb0085","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S0016-5085(03)00907-7","article-title":"Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis","volume":"125","author":"Feldstein","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.pharmthera.2026.109123_bb0090","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1002\/hep.23050","article-title":"Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: A multicenter validation study","volume":"50","author":"Feldstein","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmthera.2026.109123_bb0095","series-title":"FDA Approves First Treatment for Patients with Liver Scarring Due to Fatty Liver Disease","author":"Food, U. S., & Drug, A","year":"2024"},{"key":"10.1016\/j.pharmthera.2026.109123_bb0100","series-title":"FDA Accepts Proposal for Reasonably Likely Surrogate Endpoint for 'MASH' All-Cause Mortality or Liver-Related Events","author":"Food, U. S., & Drug, A","year":"2025"},{"key":"10.1016\/j.pharmthera.2026.109123_bb0105","series-title":"FDA Approves Treatment for Serious Liver Disease Known as 'MASH'","author":"Food, U. S., & Drug, A","year":"2025"},{"key":"10.1016\/j.pharmthera.2026.109123_bb0110","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","article-title":"Mechanisms of NAFLD development and therapeutic strategies","volume":"24","author":"Friedman","year":"2018","journal-title":"Nature Medicine"},{"key":"10.1016\/j.pharmthera.2026.109123_bb0115","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.15252\/emmm.201403856","article-title":"A positive feedback loop between RIP3 and JNK controls non-alcoholic steatohepatitis","volume":"6","author":"Gautheron","year":"2014","journal-title":"EMBO Molecular Medicine"},{"key":"10.1016\/j.pharmthera.2026.109123_bb0120","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1194\/jlr.M038638","article-title":"Obese adipocytes show ultrastructural features of stressed cells and die of pyroptosis","volume":"54","author":"Giordano","year":"2013","journal-title":"Journal of Lipid Research"},{"key":"10.1016\/j.pharmthera.2026.109123_bb0125","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.jhep.2017.07.027","article-title":"Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD","volume":"67","author":"Hagstrom","year":"2017","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.pharmthera.2026.109123_bb0130","doi-asserted-by":"crossref","first-page":"e76","DOI":"10.1016\/j.jhep.2023.08.026","article-title":"99% of patients with NAFLD meet MASLD criteria and natural history is therefore identical","volume":"80","author":"Hagstrom","year":"2024","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.pharmthera.2026.109123_bb0135","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/s41591-023-02242-6","article-title":"Challenges and opportunities in NASH drug development","volume":"29","author":"Harrison","year":"2023","journal-title":"Nature Medicine"},{"key":"10.1016\/j.pharmthera.2026.109123_bb0140","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2026.109123_bb0145","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1016\/j.cgh.2023.03.041","article-title":"Clinical trial landscape in NASH","volume":"21","author":"Harrison","year":"2023","journal-title":"Clinical Gastroenterology and Hepatology"},{"key":"10.1016\/j.pharmthera.2026.109123_bb0150","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jhep.2020.02.027","article-title":"Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials","volume":"73","author":"Harrison","year":"2020","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.pharmthera.2026.109123_bb0155","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ymgme.2022.10.004","volume":"137","author":"Hastings","year":"2022","journal-title":"Molecular Genetics and Metabolism"},{"key":"10.1016\/j.pharmthera.2026.109123_bb0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.112131","article-title":"Platelet-instructed SPP1(+) macrophages drive myofibroblast activation in fibrosis in a CXCL4-dependent manner","volume":"42","author":"Hoeft","year":"2023","journal-title":"Cell Reports"},{"key":"10.1016\/j.pharmthera.2026.109123_bb0165","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/hep4.1801","article-title":"Role of cholesterol-associated steatohepatitis in the development of NASH","volume":"6","author":"Horn","year":"2022","journal-title":"Hepatol Commun."},{"key":"10.1016\/j.pharmthera.2026.109123_bb0170","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.3389\/fimmu.2019.02670","article-title":"Contribution of macrophage efferocytosis to liver homeostasis and disease","volume":"10","author":"Horst","year":"2019","journal-title":"Frontiers in Immunology"},{"key":"10.1016\/j.pharmthera.2026.109123_bb0175","doi-asserted-by":"crossref","first-page":"819","DOI":"10.2337\/db10-0864","article-title":"Increased expression of macrophage-inducible C-type lectin in adipose tissue of obese mice and humans","volume":"60","author":"Ichioka","year":"2011","journal-title":"Diabetes"},{"key":"10.1016\/j.pharmthera.2026.109123_bb0180","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1194\/jlr.M034876","article-title":"Hepatic cholesterol crystals and crown-like structures distinguish NASH from simple steatosis","volume":"54","author":"Ioannou","year":"2013","journal-title":"Journal of Lipid Research"},{"key":"10.1016\/j.pharmthera.2026.109123_bb0185","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1002\/hep4.1348","article-title":"Cholesterol crystals in hepatocyte lipid droplets are strongly associated with human nonalcoholic steatohepatitis","volume":"3","author":"Ioannou","year":"2019","journal-title":"Hepatol Commun."},{"key":"10.1016\/j.pharmthera.2026.109123_bb0190","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1194\/jlr.M053785","article-title":"Cholesterol-lowering drugs cause dissolution of cholesterol crystals and disperse Kupffer cell crown-like structures during resolution of NASH","volume":"56","author":"Ioannou","year":"2015","journal-title":"Journal of Lipid Research"},{"key":"10.1016\/j.pharmthera.2026.109123_bb0195","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1084\/jem.20091750","article-title":"Direct recognition of the mycobacterial glycolipid, trehalose dimycolate, by C-type lectin Mincle","volume":"206","author":"Ishikawa","year":"2009","journal-title":"The Journal of Experimental Medicine"},{"key":"10.1016\/j.pharmthera.2026.109123_bb0200","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0082163","article-title":"Hepatic crown-like structure: A unique histological feature in non-alcoholic steatohepatitis in mice and humans","volume":"8","author":"Itoh","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2026.109123_bb0205","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.92902","article-title":"CD11c+ resident macrophages drive hepatocyte death-triggered liver fibrosis in a murine model of nonalcoholic steatohepatitis","volume":"2","author":"Itoh","year":"2017","journal-title":"JCI Insight"},{"key":"10.1016\/j.pharmthera.2026.109123_bb0210","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1016\/j.ajpath.2011.07.014","article-title":"Melanocortin 4 receptor-deficient mice as a novel mouse model of nonalcoholic steatohepatitis","volume":"179","author":"Itoh","year":"2011","journal-title":"The American Journal of Pathology"},{"key":"10.1016\/j.pharmthera.2026.109123_bb0215","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20220681","article-title":"Lysosomal cholesterol overload in macrophages promotes liver fibrosis in a mouse model of NASH","volume":"220","author":"Itoh","year":"2023","journal-title":"The Journal of Experimental Medicine"},{"key":"10.1016\/j.pharmthera.2026.109123_bb0220","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.cell.2019.05.054","article-title":"Lipid-associated macrophages control metabolic homeostasis in a Trem2-dependent manner","volume":"178","author":"Jaitin","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2026.109123_bb0225","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00646-2019","article-title":"A spatially restricted fibrotic niche in pulmonary fibrosis is sustained by M-CSF\/M-CSFR signalling in monocyte-derived alveolar macrophages","volume":"55","author":"Joshi","year":"2020","journal-title":"The European Respiratory Journal"},{"key":"10.1016\/j.pharmthera.2026.109123_bb0230","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","author":"Kleiner","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmthera.2026.109123_bb0235","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.2337\/db24-0762","article-title":"Novel cell-to-cell communications between macrophages and fibroblasts regulate obesity-induced adipose tissue fibrosis","volume":"74","author":"Kohda","year":"2025","journal-title":"Diabetes"},{"key":"10.1016\/j.pharmthera.2026.109123_bb0240","doi-asserted-by":"crossref","first-page":"3466","DOI":"10.1172\/JCI42845","article-title":"Weight loss and lipolysis promote a dynamic immune response in murine adipose tissue","volume":"120","author":"Kosteli","year":"2010","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/j.pharmthera.2026.109123_bb0245","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1172\/JCI88881","article-title":"Liver inflammation and fibrosis","volume":"127","author":"Koyama","year":"2017","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/j.pharmthera.2026.109123_bb0250","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/nri.2017.11","article-title":"Liver macrophages in tissue homeostasis and disease","volume":"17","author":"Krenkel","year":"2017","journal-title":"Nature Reviews. Immunology"},{"key":"10.1016\/j.pharmthera.2026.109123_bb0255","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.1073\/pnas.0630588100","article-title":"Triglyceride accumulation protects against fatty acid-induced lipotoxicity","volume":"100","author":"Listenberger","year":"2003","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2026.109123_bb0260","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/S0025-6196(24)00530-5","article-title":"Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease","volume":"55","author":"Ludwig","year":"1980","journal-title":"Mayo Clinic Proceedings"},{"key":"10.1016\/j.pharmthera.2026.109123_bb0265","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1053\/j.gastro.2014.07.018","article-title":"Cell death and cell death responses in liver disease: Mechanisms and clinical relevance","volume":"147","author":"Luedde","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.pharmthera.2026.109123_bb0270","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1172\/JCI29881","article-title":"Obesity induces a phenotypic switch in adipose tissue macrophage polarization","volume":"117","author":"Lumeng","year":"2007","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/j.pharmthera.2026.109123_bb0275","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/s41593-019-0566-1","article-title":"Lipid-droplet-accumulating microglia represent a dysfunctional and proinflammatory state in the aging brain","volume":"23","author":"Marschallinger","year":"2020","journal-title":"Nature Neuroscience"},{"key":"10.1016\/j.pharmthera.2026.109123_bb0280","doi-asserted-by":"crossref","first-page":"5039","DOI":"10.4049\/jimmunol.163.9.5039","article-title":"A novel LPS-inducible C-type lectin is a transcriptional target of NF-IL6 in macrophages","volume":"163","author":"Matsumoto","year":"1999","journal-title":"Journal of Immunology"},{"key":"10.1016\/j.pharmthera.2026.109123_bb0285","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02441-2018","article-title":"Proliferating SPP1\/MERTK-expressing macrophages in idiopathic pulmonary fibrosis","volume":"54","author":"Morse","year":"2019","journal-title":"The European Respiratory Journal"},{"key":"10.1016\/j.pharmthera.2026.109123_bb0290","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1053\/j.gastro.2018.06.031","article-title":"Bioactive lipid species and metabolic pathways in progression and resolution of nonalcoholic steatohepatitis","volume":"155","author":"Musso","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.pharmthera.2026.109123_bb0295","doi-asserted-by":"crossref","first-page":"e155","DOI":"10.1016\/j.jhep.2023.12.030","article-title":"Almost identical values of various non-invasive indexes for hepatic fibrosis and steatosis between NAFLD and MASLD in Asia","volume":"80","author":"Nakano","year":"2024","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.pharmthera.2026.109123_bb0300","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1002\/hep.23719","article-title":"Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: The central role of nontriglyceride fatty acid metabolites","volume":"52","author":"Neuschwander-Tetri","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmthera.2026.109123_bb0305","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1016\/S0140-6736(17)31465-4","article-title":"Intrathecal 2-hydroxypropyl-beta-cyclodextrin decreases neurological disease progression in Niemann-Pick disease, type C1: A non-randomised, open-label, phase 1-2 trial","volume":"390","author":"Ory","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2026.109123_bb0310","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s41598-025-28897-4","article-title":"Altered glycolipid metabolism during acute kidney injury exacerbates renal inflammation","volume":"16","author":"Osada","year":"2025","journal-title":"Scientific Reports"},{"key":"10.1016\/j.pharmthera.2026.109123_bb0315","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1038\/s41419-020-03003-w","article-title":"Understanding lipotoxicity in NAFLD pathogenesis: Is CD36 a key driver?","volume":"11","author":"Rada","year":"2020","journal-title":"Cell Death & Disease"},{"key":"10.1016\/j.pharmthera.2026.109123_bb0320","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/s41586-019-1631-3","article-title":"Resolving the fibrotic niche of human liver cirrhosis at single-cell level","volume":"575","author":"Ramachandran","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2026.109123_bb0325","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1016\/j.jhep.2023.07.017","article-title":"Confirmatory biomarker diagnostic studies are not needed when transitioning from NAFLD to MASLD","volume":"80","author":"Ratziu","year":"2024","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.pharmthera.2026.109123_bb0330","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1053\/j.gastro.2005.03.084","article-title":"Sampling variability of liver biopsy in nonalcoholic fatty liver disease","volume":"128","author":"Ratziu","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.pharmthera.2026.109123_bb0335","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.immuni.2020.08.004","article-title":"Osteopontin expression identifies a subset of recruited macrophages distinct from Kupffer cells in the fatty liver","volume":"53","author":"Remmerie","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.pharmthera.2026.109123_bb0340","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1164\/rccm.201712-2410OC","article-title":"Single-cell transcriptomic analysis of human lung provides insights into the pathobiology of pulmonary fibrosis","volume":"199","author":"Reyfman","year":"2019","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1016\/j.pharmthera.2026.109123_bb0345","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgmr.2021.100772","article-title":"A phase 1\/2 open label nonrandomized clinical trial of intravenous 2-hydroxypropyl-beta-cyclodextrin for acute liver disease in infants with Niemann-Pick C1","volume":"28","author":"Reynolds","year":"2021","journal-title":"Molecular Genetics and Metabolism Reports"},{"key":"10.1016\/j.pharmthera.2026.109123_bb0350","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"78","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmthera.2026.109123_bb0355","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmthera.2026.109123_bb0360","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/s41575-026-01187-8","article-title":"Therapeutic targets for metabolic dysfunction-associated steatohepatitis: A personalized approach to disease management","volume":"23","author":"Rinella","year":"2026","journal-title":"Nature Reviews. Gastroenterology & Hepatology"},{"key":"10.1016\/j.pharmthera.2026.109123_bb0365","doi-asserted-by":"crossref","first-page":"5477","DOI":"10.1073\/pnas.0914309107","article-title":"Endocytosis of beta-cyclodextrins is responsible for cholesterol reduction in Niemann-Pick type C mutant cells","volume":"107","author":"Rosenbaum","year":"2010","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2026.109123_bb0370","article-title":"Liver lipid droplet cholesterol content is a key determinant of metabolic dysfunction-associated steatohepatitis","volume":"122","author":"Sakuma","year":"2025","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2026.109123_bb0375","first-page":"283","article-title":"Nonalcoholic fatty liver disease","volume":"8","author":"Schaffner","year":"1986","journal-title":"Progress in Liver Diseases"},{"key":"10.1016\/j.pharmthera.2026.109123_bb0380","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1053\/j.gastro.2019.11.311","article-title":"Mechanisms of fibrosis development in nonalcoholic steatohepatitis","volume":"158","author":"Schwabe","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.pharmthera.2026.109123_bb0385","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1002\/hep.27332","article-title":"Hepatic inflammation and fibrosis: Functional links and key pathways","volume":"61","author":"Seki","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmthera.2026.109123_bb0390","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adv2106","article-title":"Impaired TIM4-mediated efferocytosis by liver macrophages contributes to fibrosis in metabolic dysfunction-associated steatohepatitis","volume":"17","author":"Shi","year":"2025","journal-title":"Science Translational Medicine"},{"key":"10.1016\/j.pharmthera.2026.109123_bb0395","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/j.jhep.2023.08.008","article-title":"Progression of non-alcoholic fatty liver disease and long-term outcomes: A nationwide paired liver biopsy cohort study","volume":"79","author":"Simon","year":"2023","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.pharmthera.2026.109123_bb0400","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.cgh.2014.04.014","article-title":"Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: A systematic review and meta-analysis of paired-biopsy studies","volume":"13","author":"Singh","year":"2015","journal-title":"Clinical Gastroenterology and Hepatology"},{"key":"10.1016\/j.pharmthera.2026.109123_bb0405","doi-asserted-by":"crossref","DOI":"10.1038\/s41577-026-01292-4","article-title":"Metabolite and nutrient regulation of macrophages in obesity and metabolic disease","author":"Sprenkle","year":"2026","journal-title":"Nature Reviews. Immunology"},{"key":"10.1016\/j.pharmthera.2026.109123_bb0410","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1161\/01.ATV.0000183883.72263.13","article-title":"A paracrine loop between adipocytes and macrophages aggravates inflammatory changes: Role of free fatty acids and tumor necrosis factor alpha","volume":"25","author":"Suganami","year":"2005","journal-title":"Arteriosclerosis, Thrombosis, and Vascular Biology"},{"key":"10.1016\/j.pharmthera.2026.109123_bb0415","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1161\/01.ATV.0000251608.09329.9a","article-title":"Role of the Toll-like receptor 4\/NF-kappaB pathway in saturated fatty acid-induced inflammatory changes in the interaction between adipocytes and macrophages","volume":"27","author":"Suganami","year":"2007","journal-title":"Arteriosclerosis, Thrombosis, and Vascular Biology"},{"key":"10.1016\/j.pharmthera.2026.109123_bb0420","doi-asserted-by":"crossref","first-page":"4356","DOI":"10.1038\/srep04356","article-title":"Lysosomal-specific cholesterol reduction by biocleavable polyrotaxanes for ameliorating Niemann-Pick type C disease","volume":"4","author":"Tamura","year":"2014","journal-title":"Scientific Reports"},{"key":"10.1016\/j.pharmthera.2026.109123_bb0425","doi-asserted-by":"crossref","first-page":"9442","DOI":"10.1074\/jbc.M115.636803","article-title":"beta-Cyclodextrin-threaded biocleavable polyrotaxanes ameliorate impaired autophagic flux in Niemann-Pick type C disease","volume":"290","author":"Tamura","year":"2015","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2026.109123_bb0430","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jconrel.2017.11.016","article-title":"Polyrotaxane-based systemic delivery of beta-cyclodextrins for potentiating therapeutic efficacy in a mouse model of Niemann-Pick type C disease","volume":"269","author":"Tamura","year":"2018","journal-title":"Journal of Controlled Release"},{"key":"10.1016\/j.pharmthera.2026.109123_bb0435","doi-asserted-by":"crossref","first-page":"4982","DOI":"10.1038\/ncomms5982","article-title":"Macrophage-inducible C-type lectin underlies obesity-induced adipose tissue fibrosis","volume":"5","author":"Tanaka","year":"2014","journal-title":"Nature Communications"},{"key":"10.1016\/j.pharmthera.2026.109123_bb0440","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20192230","article-title":"C-type lectin Mincle mediates cell death-triggered inflammation in acute kidney injury","volume":"217","author":"Tanaka","year":"2020","journal-title":"The Journal of Experimental Medicine"},{"key":"10.1016\/j.pharmthera.2026.109123_bb0445","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1053\/j.gastro.2020.01.043","article-title":"Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis","volume":"158","author":"Taylor","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.pharmthera.2026.109123_bb0450","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1002\/hep.31518","article-title":"Multiple parallel hits hypothesis in nonalcoholic fatty liver disease: Revisited after a decade","volume":"73","author":"Tilg","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmthera.2026.109123_bb0455","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1002\/hep.24001","article-title":"Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis","volume":"52","author":"Tilg","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmthera.2026.109123_bb0460","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1136\/gutjnl-2016-313615","article-title":"MerTK expressing hepatic macrophages promote the resolution of inflammation in acute liver failure","volume":"67","author":"Triantafyllou","year":"2018","journal-title":"Gut"},{"key":"10.1016\/j.pharmthera.2026.109123_bb0465","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/s41419-019-1678-y","article-title":"Hepatic ferroptosis plays an important role as the trigger for initiating inflammation in nonalcoholic steatohepatitis","volume":"10","author":"Tsurusaki","year":"2019","journal-title":"Cell Death & Disease"},{"key":"10.1016\/j.pharmthera.2026.109123_bb0470","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1038\/s42255-024-01043-6","article-title":"An unbiased ranking of murine dietary models based on their proximity to human metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"6","author":"Vacca","year":"2024","journal-title":"Nature Metabolism"},{"key":"10.1016\/j.pharmthera.2026.109123_bb0475","doi-asserted-by":"crossref","first-page":"453","DOI":"10.14309\/ajg.0000000000001606","article-title":"Fibrosis-4 index can independently predict major adverse cardiovascular events in nonalcoholic fatty liver disease","volume":"117","author":"Vieira Barbosa","year":"2022","journal-title":"The American Journal of Gastroenterology"},{"key":"10.1016\/j.pharmthera.2026.109123_bb0480","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/s41575-020-00408-y","article-title":"Therapeutic pipeline in nonalcoholic steatohepatitis","volume":"18","author":"Vuppalanchi","year":"2021","journal-title":"Nature Reviews. Gastroenterology & Hepatology"},{"key":"10.1016\/j.pharmthera.2026.109123_bb0485","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202501121R","article-title":"Transient dietary intervention induces healthy adipose tissue expansion and metabolically healthy obesity in mice","volume":"39","author":"Wada","year":"2025","journal-title":"The FASEB Journal"},{"key":"10.1016\/j.pharmthera.2026.109123_bb0490","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.immuni.2022.11.013","article-title":"Prolonged hypernutrition impairs TREM2-dependent efferocytosis to license chronic liver inflammation and NASH development","volume":"56","author":"Wang","year":"2023","journal-title":"Immunity"},{"key":"10.1016\/j.pharmthera.2026.109123_bb0495","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1172\/JCI200319246","article-title":"Obesity is associated with macrophage accumulation in adipose tissue","volume":"112","author":"Weisberg","year":"2003","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/j.pharmthera.2026.109123_bb0500","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/hep.21223","article-title":"In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease","volume":"44","author":"Wieckowska","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmthera.2026.109123_bb0505","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/nature12034","article-title":"Macrophage biology in development, homeostasis and disease","volume":"496","author":"Wynn","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2026.109123_bb0510","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.molcel.2019.07.028","article-title":"Landscape of intercellular crosstalk in healthy and NASH liver revealed by single-cell secretome gene analysis","volume":"75","author":"Xiong","year":"2019","journal-title":"Molecular Cell"},{"key":"10.1016\/j.pharmthera.2026.109123_bb0515","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1172\/JCI200319451","article-title":"Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance","volume":"112","author":"Xu","year":"2003","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/j.pharmthera.2026.109123_bb0520","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/s41420-024-02168-z","article-title":"Targeting cell death in NAFLD: Mechanisms and targeted therapies","volume":"10","author":"Xu","year":"2024","journal-title":"Cell Death Discovery"},{"key":"10.1016\/j.pharmthera.2026.109123_bb0525","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1038\/ni.1651","article-title":"Mincle is an ITAM-coupled activating receptor that senses damaged cells","volume":"9","author":"Yamasaki","year":"2008","journal-title":"Nature Immunology"},{"key":"10.1016\/j.pharmthera.2026.109123_bb0530","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): A systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmthera.2026.109123_bb0535","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.jhep.2024.01.014","article-title":"Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease","volume":"80","author":"Younossi","year":"2024","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.pharmthera.2026.109123_bb0540","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","article-title":"Obeticholic acid for the treatment of non-alcoholic steatohepatitis: Interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial","volume":"394","author":"Younossi","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2026.109123_bb0545","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmr.2024.100018","article-title":"Pharmacological treatment for metabolic dysfunction-associated steatotic liver disease and related disorders: Current and emerging therapeutic options","volume":"77","author":"Zhang","year":"2025","journal-title":"Pharmacological Reviews"},{"key":"10.1016\/j.pharmthera.2026.109123_bb0550","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/j.bbamem.2007.03.026","article-title":"Use of cyclodextrins to manipulate plasma membrane cholesterol content: Evidence, misconceptions and control strategies","volume":"1768","author":"Zidovetzki","year":"2007","journal-title":"Biochimica et Biophysica Acta"}],"container-title":["Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725826001506?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725826001506?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T16:03:51Z","timestamp":1794413031000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725826001506"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":110,"alternative-id":["S0163725826001506"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2026.109123","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cell death-induced chronic inflammation as a therapeutic target for metabolic dysfunction-associated steatohepatitis","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2026.109123","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"109123"}}